DEXCOM INC (DC4.DE) Stock Fundamental Analysis
FRA:DC4 - Deutsche Boerse Ag - US2521311074 - Common Stock - Currency: EUR
Taking everything into account, DC4 scores 6 out of 10 in our fundamental rating. DC4 was compared to 55 industry peers in the Health Care Equipment & Supplies industry. DC4 scores excellent on profitability, but there are some minor concerns on its financial health. DC4 shows excellent growth, but is valued quite expensive already. With these ratings, DC4 could be worth investigating further for growth investing!.
1. Profitability
1.1 Basic Checks
DC4 had positive earnings in the past year.
In the past year DC4 had a positive cash flow from operations.
DC4 had positive earnings in each of the past 5 years.
In the past 5 years DC4 always reported a positive cash flow from operatings.
1.2 Ratios
The Return On Assets of DC4 (10.71%) is better than 90.20% of its industry peers.
DC4 has a better Return On Equity (34.40%) than 96.08% of its industry peers.
With an excellent Return On Invested Capital value of 11.41%, DC4 belongs to the best of the industry, outperforming 90.20% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for DC4 is in line with the industry average of 8.18%.
The last Return On Invested Capital (11.41%) for DC4 is above the 3 year average (8.57%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.71% | ||
| ROE | 34.4% | ||
| ROIC | 11.41% |
ROA(3y)6.46%
ROA(5y)7.28%
ROE(3y)17.6%
ROE(5y)18.87%
ROIC(3y)8.57%
ROIC(5y)7.84%
1.3 Margins
Looking at the Profit Margin, with a value of 17.22%, DC4 belongs to the top of the industry, outperforming 88.24% of the companies in the same industry.
DC4's Profit Margin has declined in the last couple of years.
DC4 has a Operating Margin of 16.30%. This is in the better half of the industry: DC4 outperforms 78.43% of its industry peers.
In the last couple of years the Operating Margin of DC4 has remained more or less at the same level.
DC4's Gross Margin of 62.10% is in line compared to the rest of the industry. DC4 outperforms 54.90% of its industry peers.
In the last couple of years the Gross Margin of DC4 has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.3% | ||
| PM (TTM) | 17.22% | ||
| GM | 62.1% |
OM growth 3Y0.29%
OM growth 5YN/A
PM growth 3Y-19.38%
PM growth 5YN/A
GM growth 3Y-2.04%
GM growth 5Y-0.22%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DC4 is creating some value.
Compared to 1 year ago, DC4 has less shares outstanding
Compared to 5 years ago, DC4 has more shares outstanding
DC4 has a worse debt/assets ratio than last year.
2.2 Solvency
DC4 has an Altman-Z score of 6.47. This indicates that DC4 is financially healthy and has little risk of bankruptcy at the moment.
DC4 has a better Altman-Z score (6.47) than 90.20% of its industry peers.
DC4 has a debt to FCF ratio of 4.67. This is a neutral value as DC4 would need 4.67 years to pay back of all of its debts.
DC4 has a Debt to FCF ratio of 4.67. This is in the better half of the industry: DC4 outperforms 72.55% of its industry peers.
A Debt/Equity ratio of 1.26 is on the high side and indicates that DC4 has dependencies on debt financing.
DC4's Debt to Equity ratio of 1.26 is on the low side compared to the rest of the industry. DC4 is outperformed by 88.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 4.67 | ||
| Altman-Z | 6.47 |
ROIC/WACC1.31
WACC8.69%
2.3 Liquidity
A Current Ratio of 2.46 indicates that DC4 has no problem at all paying its short term obligations.
DC4's Current ratio of 2.46 is fine compared to the rest of the industry. DC4 outperforms 66.67% of its industry peers.
DC4 has a Quick Ratio of 2.12. This indicates that DC4 is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.12, DC4 is in the better half of the industry, outperforming 74.51% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.46 | ||
| Quick Ratio | 2.12 |
3. Growth
3.1 Past
DC4 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.93%, which is quite impressive.
DC4 shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 83.54% yearly.
Looking at the last year, DC4 shows a quite strong growth in Revenue. The Revenue has grown by 16.19% in the last year.
Measured over the past years, DC4 shows a very strong growth in Revenue. The Revenue has been growing by 28.56% on average per year.
EPS 1Y (TTM)25.93%
EPS 3Y25.17%
EPS 5Y83.54%
EPS Q2Q%-10%
Revenue 1Y (TTM)16.19%
Revenue growth 3Y23.42%
Revenue growth 5Y28.56%
Sales Q2Q%1.97%
3.2 Future
Based on estimates for the next years, DC4 will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.56% on average per year.
The Revenue is expected to grow by 14.25% on average over the next years. This is quite good.
EPS Next Y15.31%
EPS Next 2Y17.03%
EPS Next 3Y18.59%
EPS Next 5Y18.56%
Revenue Next Year11.48%
Revenue Next 2Y13.09%
Revenue Next 3Y13.79%
Revenue Next 5Y14.25%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 51.69, DC4 can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of DC4 is on the same level as its industry peers.
DC4 is valuated expensively when we compare the Price/Earnings ratio to 28.64, which is the current average of the S&P500 Index.
With a Price/Forward Earnings ratio of 42.55, DC4 can be considered very expensive at the moment.
64.71% of the companies in the same industry are cheaper than DC4, based on the Price/Forward Earnings ratio.
When comparing the Price/Forward Earnings ratio of DC4 to the average of the S&P500 Index (24.51), we can say DC4 is valued expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.69 | ||
| Fwd PE | 42.55 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DC4 is on the same level as its industry peers.
The rest of the industry has a similar Price/Free Cash Flow ratio as DC4.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 64.24 | ||
| EV/EBITDA | 37.93 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DC4 does not grow enough to justify the current Price/Earnings ratio.
DC4 has a very decent profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as DC4's earnings are expected to grow with 18.59% in the coming years.
PEG (NY)3.38
PEG (5Y)0.62
EPS Next 2Y17.03%
EPS Next 3Y18.59%
5. Dividend
5.1 Amount
No dividends for DC4!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
DEXCOM INC
FRA:DC4 (1/22/2025, 7:00:00 PM)
84.26
+1.87 (+2.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners98.81%
Inst Owner ChangeN/A
Ins Owners0.33%
Ins Owner ChangeN/A
Market Cap32.91B
Analysts84.38
Price Target97.94 (16.24%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)5.38%
Min EPS beat(2)1.51%
Max EPS beat(2)9.24%
EPS beat(4)4
Avg EPS beat(4)10.13%
Min EPS beat(4)1.51%
Max EPS beat(4)16.17%
EPS beat(8)8
Avg EPS beat(8)21%
EPS beat(12)9
Avg EPS beat(12)9.01%
EPS beat(16)12
Avg EPS beat(16)13.61%
Revenue beat(2)0
Avg Revenue beat(2)-3.32%
Min Revenue beat(2)-4.99%
Max Revenue beat(2)-1.66%
Revenue beat(4)0
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-4.99%
Max Revenue beat(4)-0.14%
Revenue beat(8)3
Avg Revenue beat(8)-0.58%
Revenue beat(12)4
Avg Revenue beat(12)-0.78%
Revenue beat(16)8
Avg Revenue beat(16)0.18%
PT rev (1m)5.3%
PT rev (3m)8.74%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-7.56%
EPS NY rev (1m)0%
EPS NY rev (3m)0.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-10.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.1%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 51.69 | ||
| Fwd PE | 42.55 | ||
| P/S | 8.69 | ||
| P/FCF | 64.24 | ||
| P/OCF | 41.83 | ||
| P/B | 17.37 | ||
| P/tB | 18.59 | ||
| EV/EBITDA | 37.93 |
EPS(TTM)1.63
EY1.93%
EPS(NY)1.98
Fwd EY2.35%
FCF(TTM)1.31
FCFY1.56%
OCF(TTM)2.01
OCFY2.39%
SpS9.69
BVpS4.85
TBVpS4.53
PEG (NY)3.38
PEG (5Y)0.62
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 10.71% | ||
| ROE | 34.4% | ||
| ROCE | 13.95% | ||
| ROIC | 11.41% | ||
| ROICexc | 24.78% | ||
| ROICexgc | 26.39% | ||
| OM | 16.3% | ||
| PM (TTM) | 17.22% | ||
| GM | 62.1% | ||
| FCFM | 13.53% |
ROA(3y)6.46%
ROA(5y)7.28%
ROE(3y)17.6%
ROE(5y)18.87%
ROIC(3y)8.57%
ROIC(5y)7.84%
ROICexc(3y)23.92%
ROICexc(5y)24.92%
ROICexgc(3y)27.11%
ROICexgc(5y)27.14%
ROCE(3y)10.48%
ROCE(5y)9.58%
ROICexcg growth 3Y-0.44%
ROICexcg growth 5YN/A
ROICexc growth 3Y-2.54%
ROICexc growth 5YN/A
OM growth 3Y0.29%
OM growth 5YN/A
PM growth 3Y-19.38%
PM growth 5YN/A
GM growth 3Y-2.04%
GM growth 5Y-0.22%
F-Score6
Asset Turnover0.62
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.26 | ||
| Debt/FCF | 4.67 | ||
| Debt/EBITDA | 2.91 | ||
| Cap/Depr | 134.98% | ||
| Cap/Sales | 7.25% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.88% | ||
| Profit Quality | 78.58% | ||
| Current Ratio | 2.46 | ||
| Quick Ratio | 2.12 | ||
| Altman-Z | 6.47 |
F-Score6
WACC8.69%
ROIC/WACC1.31
Cap/Depr(3y)247.59%
Cap/Depr(5y)281.79%
Cap/Sales(3y)11.65%
Cap/Sales(5y)11.5%
Profit Quality(3y)69.47%
Profit Quality(5y)78.35%
High Growth Momentum
Growth
EPS 1Y (TTM)25.93%
EPS 3Y25.17%
EPS 5Y83.54%
EPS Q2Q%-10%
EPS Next Y15.31%
EPS Next 2Y17.03%
EPS Next 3Y18.59%
EPS Next 5Y18.56%
Revenue 1Y (TTM)16.19%
Revenue growth 3Y23.42%
Revenue growth 5Y28.56%
Sales Q2Q%1.97%
Revenue Next Year11.48%
Revenue Next 2Y13.09%
Revenue Next 3Y13.79%
Revenue Next 5Y14.25%
EBIT growth 1Y23.94%
EBIT growth 3Y23.78%
EBIT growth 5YN/A
EBIT Next Year63.71%
EBIT Next 3Y34.02%
EBIT Next 5Y28.71%
FCF growth 1Y104.75%
FCF growth 3Y22.78%
FCF growth 5Y55.61%
OCF growth 1Y27.83%
OCF growth 3Y16.32%
OCF growth 5Y43.46%